← All trials
NCT07305805
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2025
- Primary completion
- May 17, 2026
- Completion date
- May 21, 2026
- First posted
- Dec 26, 2025
- Last posted
- Dec 26, 2025
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Novo NordiskLead sponsor
- Novo NordiskOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.